 Joshua Yarrow
Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Injuries | 14 | 2022 | 184 | 6.900 |
Why?
| | Testosterone | 25 | 2019 | 350 | 6.630 |
Why?
| | Bone and Bones | 10 | 2022 | 288 | 3.770 |
Why?
| | Muscle, Skeletal | 17 | 2021 | 1515 | 2.450 |
Why?
| | Androgens | 11 | 2018 | 167 | 1.980 |
Why?
| | Dihydrotestosterone | 6 | 2015 | 39 | 1.670 |
Why?
| | Trenbolone Acetate | 7 | 2018 | 11 | 1.500 |
Why?
| | Bone Remodeling | 3 | 2022 | 64 | 1.400 |
Why?
| | Muscular Atrophy | 3 | 2021 | 80 | 1.400 |
Why?
| | Osteogenesis | 2 | 2021 | 213 | 1.240 |
Why?
| | Osteoporosis | 5 | 2015 | 226 | 1.210 |
Why?
| | Prostate | 4 | 2017 | 158 | 1.120 |
Why?
| | Rats | 19 | 2022 | 5329 | 1.110 |
Why?
| | Rats, Sprague-Dawley | 11 | 2022 | 2431 | 1.090 |
Why?
| | Bone Morphogenetic Proteins | 2 | 2018 | 137 | 1.090 |
Why?
| | Finasteride | 5 | 2017 | 35 | 0.990 |
Why?
| | Estradiol | 5 | 2018 | 472 | 0.940 |
Why?
| | Bone Density | 7 | 2022 | 447 | 0.920 |
Why?
| | Exercise | 6 | 2022 | 1647 | 0.860 |
Why?
| | Cancellous Bone | 2 | 2019 | 21 | 0.850 |
Why?
| | Hormone Replacement Therapy | 4 | 2018 | 80 | 0.850 |
Why?
| | Estrogens | 4 | 2018 | 327 | 0.820 |
Why?
| | Ovariectomy | 3 | 2018 | 124 | 0.780 |
Why?
| | Bone Resorption | 2 | 2018 | 80 | 0.770 |
Why?
| | Animals | 29 | 2022 | 33107 | 0.700 |
Why?
| | Relaxin | 1 | 2019 | 15 | 0.690 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 168 | 0.690 |
Why?
| | Skull Fractures | 1 | 2019 | 30 | 0.680 |
Why?
| | X-Ray Microtomography | 4 | 2022 | 79 | 0.680 |
Why?
| | Physical Therapy Modalities | 1 | 2022 | 274 | 0.660 |
Why?
| | Hypertriglyceridemia | 1 | 2018 | 38 | 0.630 |
Why?
| | Neuromuscular Junction | 1 | 2018 | 53 | 0.630 |
Why?
| | Orchiectomy | 6 | 2018 | 57 | 0.620 |
Why?
| | Male | 39 | 2022 | 57376 | 0.620 |
Why?
| | Physical Conditioning, Animal | 1 | 2019 | 204 | 0.610 |
Why?
| | Anabolic Agents | 4 | 2014 | 12 | 0.600 |
Why?
| | Muscle Weakness | 1 | 2018 | 82 | 0.600 |
Why?
| | Arthritis | 1 | 2018 | 113 | 0.590 |
Why?
| | Cholestenone 5 alpha-Reductase | 2 | 2015 | 3 | 0.560 |
Why?
| | Antibodies, Neutralizing | 1 | 2018 | 225 | 0.550 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 442 | 0.550 |
Why?
| | Recovery of Function | 1 | 2019 | 603 | 0.540 |
Why?
| | Diet, High-Fat | 2 | 2021 | 247 | 0.530 |
Why?
| | Fructose | 1 | 2016 | 198 | 0.480 |
Why?
| | Sarcopenia | 1 | 2015 | 72 | 0.460 |
Why?
| | Muscles | 2 | 2014 | 332 | 0.460 |
Why?
| | Muscle Strength | 5 | 2018 | 283 | 0.460 |
Why?
| | Rats, Inbred F344 | 7 | 2018 | 245 | 0.460 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 195 | 0.450 |
Why?
| | Hypogonadism | 4 | 2015 | 77 | 0.450 |
Why?
| | Hindlimb Suspension | 1 | 2012 | 24 | 0.440 |
Why?
| | Human Growth Hormone | 2 | 2012 | 37 | 0.420 |
Why?
| | Resistance Training | 2 | 2012 | 120 | 0.400 |
Why?
| | Adiponectin | 1 | 2012 | 224 | 0.380 |
Why?
| | Feeding Behavior | 1 | 2016 | 594 | 0.370 |
Why?
| | Physical Endurance | 2 | 2010 | 231 | 0.350 |
Why?
| | Hemoglobins | 2 | 2012 | 318 | 0.350 |
Why?
| | Bone Diseases, Metabolic | 2 | 2021 | 60 | 0.350 |
Why?
| | Lactic Acid | 2 | 2008 | 276 | 0.350 |
Why?
| | Aromatase | 3 | 2015 | 31 | 0.350 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2010 | 117 | 0.340 |
Why?
| | Hypertension | 1 | 2018 | 1198 | 0.340 |
Why?
| | Periodontitis | 2 | 2019 | 42 | 0.340 |
Why?
| | Physical Education and Training | 1 | 2008 | 62 | 0.320 |
Why?
| | Aging | 2 | 2015 | 1673 | 0.320 |
Why?
| | Neurosecretory Systems | 1 | 2007 | 33 | 0.300 |
Why?
| | Weight Lifting | 1 | 2007 | 30 | 0.300 |
Why?
| | Receptors, Androgen | 4 | 2018 | 132 | 0.290 |
Why?
| | 5-alpha Reductase Inhibitors | 2 | 2017 | 16 | 0.280 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2018 | 1237 | 0.270 |
Why?
| | Atrophy | 2 | 2018 | 164 | 0.270 |
Why?
| | Adipose Tissue | 2 | 2021 | 595 | 0.270 |
Why?
| | Adiposity | 1 | 2011 | 508 | 0.270 |
Why?
| | Genetic Markers | 2 | 2018 | 338 | 0.260 |
Why?
| | Humans | 27 | 2022 | 118066 | 0.260 |
Why?
| | Organ Size | 5 | 2018 | 460 | 0.260 |
Why?
| | Obesity | 1 | 2018 | 2715 | 0.250 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 118 | 0.250 |
Why?
| | Adaptation, Physiological | 1 | 2008 | 501 | 0.240 |
Why?
| | Disease Models, Animal | 3 | 2019 | 3670 | 0.230 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 1795 | 0.220 |
Why?
| | Perfusion | 1 | 2022 | 152 | 0.210 |
Why?
| | Regeneration | 2 | 2021 | 166 | 0.200 |
Why?
| | Body Weight | 4 | 2016 | 923 | 0.200 |
Why?
| | Cachexia | 1 | 2021 | 53 | 0.190 |
Why?
| | Exercise Therapy | 3 | 2021 | 355 | 0.190 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2020 | 5 | 0.180 |
Why?
| | Contusions | 1 | 2020 | 20 | 0.180 |
Why?
| | Chemokine CXCL1 | 1 | 2020 | 67 | 0.180 |
Why?
| | Rats, Inbred Lew | 1 | 2019 | 87 | 0.180 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 174 | 0.180 |
Why?
| | Infusions, Subcutaneous | 1 | 2019 | 19 | 0.170 |
Why?
| | Bisphosphonate-Associated Osteonecrosis of the Jaw | 1 | 2019 | 1 | 0.170 |
Why?
| | Signal Transduction | 5 | 2021 | 4677 | 0.170 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 210 | 0.170 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 963 | 0.170 |
Why?
| | Post-Concussion Syndrome | 1 | 2021 | 136 | 0.170 |
Why?
| | Pressure Ulcer | 1 | 2019 | 33 | 0.170 |
Why?
| | Long-Term Care | 1 | 2019 | 74 | 0.160 |
Why?
| | Cortical Bone | 1 | 2018 | 18 | 0.160 |
Why?
| | Bone Density Conservation Agents | 1 | 2019 | 61 | 0.160 |
Why?
| | Drug Administration Routes | 1 | 2018 | 42 | 0.160 |
Why?
| | Multimorbidity | 1 | 2018 | 30 | 0.160 |
Why?
| | Interleukins | 1 | 2020 | 242 | 0.160 |
Why?
| | Hypothalamus | 1 | 2018 | 155 | 0.150 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2021 | 277 | 0.150 |
Why?
| | Prevalence | 3 | 2019 | 2321 | 0.150 |
Why?
| | Hand Strength | 1 | 2018 | 99 | 0.150 |
Why?
| | Growth Hormone | 2 | 2008 | 107 | 0.150 |
Why?
| | Leptin | 1 | 2018 | 228 | 0.150 |
Why?
| | Nutrition Surveys | 1 | 2018 | 232 | 0.140 |
Why?
| | Skin | 1 | 2021 | 658 | 0.140 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 150 | 0.140 |
Why?
| | Up-Regulation | 1 | 2020 | 861 | 0.140 |
Why?
| | Biomarkers | 3 | 2016 | 3564 | 0.140 |
Why?
| | Adult | 7 | 2021 | 31230 | 0.140 |
Why?
| | Eating | 1 | 2018 | 366 | 0.140 |
Why?
| | Aged | 8 | 2021 | 19557 | 0.140 |
Why?
| | Motor Neurons | 1 | 2018 | 213 | 0.140 |
Why?
| | Pilot Projects | 2 | 2011 | 1405 | 0.140 |
Why?
| | Placebos | 2 | 2014 | 200 | 0.140 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1301 | 0.130 |
Why?
| | Adipogenesis | 1 | 2016 | 47 | 0.130 |
Why?
| | Athletic Injuries | 1 | 2021 | 476 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 2 | 2017 | 418 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1159 | 0.120 |
Why?
| | Body Composition | 2 | 2016 | 644 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 719 | 0.120 |
Why?
| | Aromatase Inhibitors | 1 | 2014 | 50 | 0.120 |
Why?
| | Brain Concussion | 1 | 2021 | 461 | 0.120 |
Why?
| | Injections | 1 | 2015 | 167 | 0.120 |
Why?
| | Bone Marrow | 1 | 2016 | 250 | 0.120 |
Why?
| | Injections, Intramuscular | 1 | 2014 | 116 | 0.120 |
Why?
| | Adipocytes | 1 | 2016 | 195 | 0.120 |
Why?
| | Random Allocation | 1 | 2015 | 344 | 0.120 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1468 | 0.120 |
Why?
| | Nitriles | 1 | 2014 | 155 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 1928 | 0.120 |
Why?
| | Triazoles | 1 | 2014 | 128 | 0.110 |
Why?
| | False Positive Reactions | 1 | 2013 | 115 | 0.110 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 4886 | 0.110 |
Why?
| | Reference Standards | 1 | 2013 | 173 | 0.110 |
Why?
| | Middle Aged | 7 | 2021 | 27434 | 0.110 |
Why?
| | Liver | 1 | 2021 | 1802 | 0.110 |
Why?
| | Minerals | 1 | 2012 | 39 | 0.110 |
Why?
| | Iron | 1 | 2014 | 246 | 0.110 |
Why?
| | Double-Blind Method | 2 | 2014 | 1679 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2020 | 2656 | 0.110 |
Why?
| | Prostatic Hyperplasia | 1 | 2012 | 38 | 0.100 |
Why?
| | Absorptiometry, Photon | 1 | 2012 | 226 | 0.100 |
Why?
| | Femur | 2 | 2012 | 199 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2652 | 0.100 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2010 | 61 | 0.090 |
Why?
| | Age Factors | 1 | 2018 | 2991 | 0.090 |
Why?
| | Inflammation | 1 | 2021 | 2545 | 0.090 |
Why?
| | Body Mass Index | 1 | 2018 | 2074 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2011 | 176 | 0.090 |
Why?
| | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2010 | 9 | 0.090 |
Why?
| | Organ Specificity | 1 | 2011 | 274 | 0.090 |
Why?
| | Erythrocytes | 1 | 2014 | 619 | 0.090 |
Why?
| | Osteocalcin | 1 | 2008 | 35 | 0.080 |
Why?
| | Molecular Structure | 1 | 2010 | 444 | 0.080 |
Why?
| | Tensile Strength | 1 | 2008 | 105 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2015 | 9311 | 0.080 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1323 | 0.080 |
Why?
| | Amino Acids | 2 | 2008 | 463 | 0.080 |
Why?
| | Florida | 1 | 2007 | 73 | 0.070 |
Why?
| | Rest | 1 | 2008 | 104 | 0.070 |
Why?
| | Biological Availability | 1 | 2007 | 126 | 0.070 |
Why?
| | Sex Factors | 1 | 2012 | 1764 | 0.070 |
Why?
| | Cognition | 1 | 2014 | 1023 | 0.070 |
Why?
| | Physical Exertion | 1 | 2008 | 221 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2433 | 0.070 |
Why?
| | Tibia | 1 | 2008 | 177 | 0.070 |
Why?
| | Aged, 80 and over | 2 | 2015 | 6533 | 0.070 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2008 | 154 | 0.070 |
Why?
| | Female | 7 | 2021 | 61147 | 0.070 |
Why?
| | Creatinine | 1 | 2008 | 491 | 0.070 |
Why?
| | Mice | 2 | 2021 | 15425 | 0.070 |
Why?
| | Veterans | 1 | 2017 | 1214 | 0.070 |
Why?
| | Kidney | 2 | 2012 | 1351 | 0.060 |
Why?
| | Muscle Contraction | 1 | 2008 | 414 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2433 | 0.060 |
Why?
| | Exercise Test | 1 | 2007 | 552 | 0.060 |
Why?
| | Murinae | 1 | 2021 | 2 | 0.050 |
Why?
| | United States | 1 | 2018 | 12477 | 0.050 |
Why?
| | Risk Factors | 1 | 2014 | 8950 | 0.050 |
Why?
| | Cicatrix | 1 | 2021 | 53 | 0.050 |
Why?
| | Caseins | 1 | 2019 | 22 | 0.040 |
Why?
| | Sigmodontinae | 1 | 2019 | 2 | 0.040 |
Why?
| | Quadriplegia | 1 | 2019 | 11 | 0.040 |
Why?
| | Sucrose | 1 | 2019 | 104 | 0.040 |
Why?
| | Rats, Transgenic | 1 | 2018 | 14 | 0.040 |
Why?
| | Appetite Depressants | 1 | 2018 | 21 | 0.040 |
Why?
| | Fibrosis | 1 | 2021 | 481 | 0.040 |
Why?
| | Wnt-5a Protein | 1 | 2018 | 19 | 0.040 |
Why?
| | Paralysis | 1 | 2019 | 67 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1261 | 0.040 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2018 | 192 | 0.040 |
Why?
| | Heptanoates | 1 | 2014 | 2 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2014 | 19 | 0.030 |
Why?
| | CCN Intercellular Signaling Proteins | 1 | 2014 | 5 | 0.030 |
Why?
| | Transferrin | 1 | 2014 | 39 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 59 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1520 | 0.030 |
Why?
| | Myosins | 1 | 2014 | 129 | 0.030 |
Why?
| | Anthropometry | 1 | 2014 | 192 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2018 | 667 | 0.030 |
Why?
| | Receptors, Glucocorticoid | 1 | 2014 | 132 | 0.030 |
Why?
| | Drug Interactions | 1 | 2014 | 351 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2014 | 182 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2021 | 1167 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2014 | 352 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 816 | 0.030 |
Why?
| | Young Adult | 2 | 2021 | 10707 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2014 | 378 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2014 | 668 | 0.020 |
Why?
| | Time Factors | 2 | 2014 | 6362 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2012 | 416 | 0.020 |
Why?
| | Isotonic Contraction | 1 | 2009 | 2 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 684 | 0.020 |
Why?
| | Adolescent | 1 | 2007 | 18342 | 0.020 |
Why?
| | Databases, Factual | 1 | 2012 | 1189 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 2009 | 369 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 5072 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2008 | 345 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1285 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2021 | 12922 | 0.020 |
Why?
|
|
Yarrow's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|